Stay updated on Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the PEMDAC study is displayed, describing a completed Phase 2 trial of pembrolizumab with entinostat for metastatic uveal melanoma, including its participant criteria, study design, and outcomes.
    Difference
    43%
    Check dated 2026-11-12T20:25:09.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-10-29T20:54:52.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces updates and explains that the agency is transitioning from the term “Artificial Intelligence” to “Super Intelligence”.
    Difference
    1%
    Check dated 2026-10-22T22:25:16.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.1 to v3.7.2; the page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-15T20:55:43.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1. The page still displays a 403 Forbidden error rather than the study record.
    Difference
    0.2%
    Check dated 2026-10-08T20:56:48.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Access to the study record NCT02697630 (PEMDAC) on ClinicalTrials.gov now renders a 403 Forbidden error, replacing the previous study content. As a result, the study overview, eligibility criteria, locations, and results are not accessible to users.
    Difference
    17%
    Check dated 2026-09-24T21:34:05.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page.